Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy

Miriam Kimpton, MD, Srishti Kumar, MSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD, Kednapa Thavorn, MPharm, PhD

Blood (2019) 134 (Supplement_1): 329.

https://doi.org/10.1182/blood-2019-127286

Published: 2019

Journal Articles

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Abi Vijenthira, MD, Kelvin Chan, MD PhD, Matthew Cheung, MD MS, FRCP, Anca Prica, MD

Blood (2018) 132 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2018-99-113103

Published: 2018

Journal Articles

A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients

Alessia Pepe, Aishah Hanif, Anthony Bentley, Roderick Walker, Ludovica Frizziero, MD, Maria Caterina Putti, MD, Anna Spasiano, Caterina Borgna-Pignatti, MD, Aurelio Maggio, Maria Giovanna Neri, Antonella Meloni

Blood (2015) 126 (23): 2077.

https://doi.org/10.1182/blood.V126.23.2077.2077

Published: 2015

Journal Articles

Obinutuzumab and Chlorambucil Versus Chlorambucil Monotherapy for Treatment of Previously Untreated Chronic Lymphocytic Leukemia Where Fludarabine-Based Chemotherapy Is Considered Inappropriate: A Canadian Cost-Utility Analysis

Heather Cameron, PhD, Melissa Thompson, John-Paul Marino, Michael Duong, Ursula Becker, MSc, Christof Wiesner, PhDMPH

Blood (2014) 124 (21): 1288.

https://doi.org/10.1182/blood.V124.21.1288.1288

Published: 2014

Journal Articles

Efficacy, Tolerability and Cost Benefit of a 5-Day Azacitidine Regimen

Francesca Pierdomenico, MD, Antonio Almeida, MD, PhD

Blood (2011) 118 (21): 5034.

https://doi.org/10.1182/blood.V118.21.5034.5034

Published: 2011

Journal Articles

Molecular Testing for Response to Treatment for Chronic Myeloid Leukemia (CML) Patients: Information Available to Decision Makers on the Costs and Analytical and Clinical Validity of Alternative Approaches.

Edgar Braendle, MD, PhD, Peter Hudson, M.Sc, Ossa Diego, Ph.D, Ratcliffe Mark, Ph.D

Blood (2010) 116 (21): 4489.

https://doi.org/10.1182/blood.V116.21.4489.4489

Published: 2010

Journal Articles

Cost-Utility Analysis of Von Willebrand Disease Screening in Adolescents with Menorrhagia.

Robert F. Sidonio, Jr., MD, Kenneth J Smith, MD, MS, Margaret V. Ragni, MD, MPH

Blood (2009) 114 (22): 2476.

https://doi.org/10.1182/blood.V114.22.2476.2476

Published: 2009

Journal Articles

A Cost-Effectiveness Analysis of Coagulation Testing Prior to Tonsillectomy and Adenoidectomy in Children.

James D. Cooper, MD, Kenneth J Smith, MD, MS, Arthur Kim Ritchey, MD

Blood (2008) 112 (11): 1294.

https://doi.org/10.1182/blood.V112.11.1294.1294

Published: 2008

Journal Articles

Cytogenetic Analysis and FISH in the Evaluation of Patients with MDS: A Retrospective Analysis of Concordance Rate, Utility and Benefit of Performing Both Studies Simultaneously

Jami le Shammo, Alla Gimelfarb, Wei-Tong Hsu, Irene Dehghan- Paz, Parameswaran Venugopal, Melissa L. Larson, MD, Henry C. Fung, Mohamed Farhat, Amy Rizman, Jerome Loew, Stephanie A. Gregory

Blood (2008) 112 (11): 3630.

https://doi.org/10.1182/blood.V112.11.3630.3630

Published: 2008

Journal Articles

A Cost-Utility Analysis of Nilotinib for CML Patients Who Have Become Resistant to Imatinib.

H. Pilgrim, K. Jewitt, S. Ward

Blood (2007) 110 (11): 5175.

https://doi.org/10.1182/blood.V110.11.5175.5175

Published: 2007

Journal Articles

Clinical Efficacy and Cost Benefit of Low-Dose Granulocyte Colony-Stimulating Factor after Standard Chemotherapy in Patients with Non-Hodgkin’s Lymphoma.

Satoshi Hashino, MD, PhD, Masanobu Morioka, MD, PhD, Tatsuro Irie, MD, PhD, Noriyuki Shiroshita, MD, PhD, Tsugumichi Kawamura, MD, PhD, Sachiko Suzuki, MD, PhD, Hiroshi Iwasaki, MD, PhD, Shintaro Umehara, MD, PhD, Yasutaka Kakinoki, MD, PhD, Mitsutoshi Kurosawa, MD, PhD, Kaoru Kahata, MD, PhD, Koh Izumiyama, MD, PhD, Hajime Kobayashi, MD, Masahiro Onozawa, MD, Mutsumi Takahata, MD, Fumie Fujisawa, MD, Takeshi Kondo, MD, PhD, Masahiro Asaka, MD, PhD

Blood (2006) 108 (11): 4671.

https://doi.org/10.1182/blood.V108.11.4671.4671

Published: 2006

Journal Articles

Treatment of Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP): A Cost-Utility Analysis.

Sarah H. O’Brien, MD, A. Kim Ritchey, MD, Kenneth J. Smith, MD

Blood (2005) 106 (11): 1337.

https://doi.org/10.1182/blood.V106.11.1337.1337

Published: 2005

NARROW

Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients

Obinutuzumab and Chlorambucil Versus Chlorambucil Monotherapy for Treatment of Previously Untreated Chronic Lymphocytic Leukemia Where Fludarabine-Based Chemotherapy Is Considered Inappropriate: A Canadian Cost-Utility Analysis

Efficacy, Tolerability and Cost Benefit of a 5-Day Azacitidine Regimen

Molecular Testing for Response to Treatment for Chronic Myeloid Leukemia (CML) Patients: Information Available to Decision Makers on the Costs and Analytical and Clinical Validity of Alternative Approaches.

Cost-Utility Analysis of Von Willebrand Disease Screening in Adolescents with Menorrhagia.

A Cost-Effectiveness Analysis of Coagulation Testing Prior to Tonsillectomy and Adenoidectomy in Children.

Cytogenetic Analysis and FISH in the Evaluation of Patients with MDS: A Retrospective Analysis of Concordance Rate, Utility and Benefit of Performing Both Studies Simultaneously

A Cost-Utility Analysis of Nilotinib for CML Patients Who Have Become Resistant to Imatinib.

Clinical Efficacy and Cost Benefit of Low-Dose Granulocyte Colony-Stimulating Factor after Standard Chemotherapy in Patients with Non-Hodgkin’s Lymphoma.

Treatment of Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP): A Cost-Utility Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only